HiberGene Diagnostics collaborates to evaluate near-patient Coronavirus Test in China

DUBLIN: HiberGene Diagnostics announced that they have expedited the design of a new, rapid near-patient molecular test for Novel Coronavirus 2019-nCoV.

The Coronavirus test will undergo clinical evaluation in China in collaboration with HiberGene’s local distribution partner, Medcaptain Medical Technologies, based in Shenzhen, China.

The Loop-mediated isothermal amplification (LAMP)-based Coronavirus test uses HiberGene’s proprietary reagent format and low-complexity sample preparation protocol to quickly detect the virus in clinical samples. This allows rapid delivery of results within 60 minutes, without the need for segregated laboratory facilities or highly trained staff.

Simona Esposito, Chief Executive Officer of HiberGene said: “Our research and development team have reacted quickly to the outbreak of Coronavirus. Using the template of our CE-marked Flu and RSV respiratory tests we have been able to develop a specific and sensitive Coronavirus assay which utilises our easy-to-use, freeze-dried reagent format to facilitate near-patient testing.”

Justin Liu, CEO of Medcaptain added: “Our ongoing Chinese clinical trials of HiberGene’s Group B Streptococcus test have delivered excellent results to date. We look forward to similar performance from their new Coronavirus test, which has the potential to make significant impact on patient outcomes and infection control.”

Bookmark the permalink.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.